罗欣药业(002793) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was ¥626,810,897.48, a decrease of 61.99% year-over-year, and year-to-date revenue was ¥3,769,618,686.08, down 25.98%[4] - Net profit attributable to shareholders for Q3 2022 was -¥379,273,321.16, a decline of 372.72% year-over-year, with a year-to-date net profit of -¥497,367,412.58, down 213.99%[4] - Basic and diluted earnings per share for Q3 2022 were both -¥0.26, representing a decrease of 360.00% year-over-year, and year-to-date earnings per share were -¥0.34, down 213.33%[4] - Total operating revenue for the third quarter was CNY 3,769,618,686.08, a decrease of 26.0% compared to CNY 5,092,644,764.83 in the same period last year[27] - The net profit for the third quarter was a loss of CNY 483,606,451.16, compared to a profit of CNY 454,780,208.87 in the previous year[28] - The total comprehensive income for the third quarter was a loss of CNY 449,801,750.82, compared to a profit of CNY 448,611,358.25 in the same period last year[28] Assets and Liabilities - Total assets as of September 30, 2022, were ¥9,673,154,997.19, an increase of 1.86% compared to the end of the previous year[4] - The company's current liabilities increased to RMB 4.97 billion from RMB 4.01 billion at the beginning of the year, primarily due to an increase in short-term borrowings[25] - The company's total liabilities increased to RMB 5.38 billion from RMB 4.76 billion at the beginning of the year[25] - The company's equity attributable to shareholders decreased to RMB 3.91 billion from RMB 4.38 billion at the beginning of the year[25] Cash Flow - Cash flow from operating activities for the year-to-date was -¥1,139,298,807.70, a decline of 271.29%[4] - The company reported a significant decline in cash flow from operating activities, with a net cash outflow of CNY 1,139,298,807.70 compared to a smaller outflow of CNY 306,847,458.57 in the same period last year[29] - The company generated CNY 3,540,404,278.73 in cash from sales, down 29.0% from CNY 4,983,921,244.97 in the previous year[29] - The net cash flow from financing activities was 551,126,482.20 CNY, a decrease from 596,812,502.04 CNY in the previous year[30] - The total cash and cash equivalents at the end of the period were 764,728,288.27 CNY, down from 1,039,100,324.28 CNY year-over-year[30] - The net increase in cash and cash equivalents was -728,858,476.24 CNY, contrasting with a positive increase of 26,209,697.19 CNY in the previous year[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,744[10] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., holds 35.56% of shares, totaling 518,843,206 shares, with 213,961,841 shares pledged[10] - The second-largest shareholder, Karamay Juezhizhi Equity Investment Management Partnership, holds 9.65% of shares, totaling 140,754,819 shares, with 34,400,000 shares pledged[10] - The top ten shareholders collectively hold a significant portion of the company's equity, indicating concentrated ownership[10] - The company is actively managing its shareholder structure and performance commitments to ensure compliance with regulatory requirements[16] Performance Commitments - The company has not met its performance commitments for the years 2020 and 2021, with net profit targets of 550 million and 650 million RMB respectively not achieved[15] - The total compensation amount due from performance commitments for 2020 and 2021 is 2,291,131,273.12 RMB, equivalent to 371,334,114 shares[16] - The company plans to repurchase 33 performance compensation shares at a price of RMB 1 per year, related to the 2020 and 2021 fiscal years[17] Investments and Subsidiaries - The registered capital of the subsidiary Beijing Health is set to increase from RMB 100 million to RMB 227.9 million, with the company investing RMB 32.9 million[18] - The company has agreed to transfer 70% of the equity of its subsidiary Modern Logistics for a price of RMB 414.96 million, which will no longer be included in the consolidated financial statements[20] Other Financial Metrics - Research and development expenses were CNY 171,754,256.61, a decrease of 24.0% from CNY 225,978,379.64 in the previous year[27] - Other comprehensive income after tax was CNY 33,804,700.34, compared to a loss of CNY 6,168,850.62 in the previous year[28] - Cash received from investment recoveries was ¥118,213,229.31, a significant increase of 171.69% compared to the previous year[9] Audit and Reporting - The company did not undergo an audit for the third quarter report[31] - The report was released by the board of directors on October 28, 2022[32]